Skip to main content

Table 2 Overview of clinical characteristics and the number of somatic mutations in tumour DNA and cfDNA

From: Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients

Sample ID Stage PFS time Post-surgery CRT Blood drawing time Number of somatic mutations
Tumour Pre-surgery Post-surgery
ESCC01 PT2N0M0G2–3 IIA 5 m N 2d 12 6 0
ESCC02 PT3N0M0G2 IIB N N 3-4 h 13 2 0
ESCC03 PT2N0M0G2 IIA N N 3-4 h 13 0 0
ESCC04 PT3N0M0G2 IIA N N 3-4 h 17 6 0
ESCC05 PT3N0M0G1 IIA N N 9d 9 1 0
ESCC06 PT3N0M0G2 IIA N N 5d 3 0 0
ESCC07 PT3N0M0G1 IIA 12 m Y 3-4 h 3 NA 1
ESCC08 PT3N1M0G1 IIIB N N 3-4 h 9 3 0
ESCC09 PT4aN0M0G2 IIIB N N 3-4 h 10 8 0
ESCC10 PT4aN0M0G2 IIIB N N 9d 20 16 0
ESCC11 PT3N1M0G3 IIIB 4 m N 3-4 h 5 NA 0
ESCC12 PT3N1M0G2 IIIB N Y 3-4 h 2 0 0
ESCC13 PT3N1M0G2 IIIB N Y 3-4 h 2 0 0
ESCC14 PT2N1M0G2 IIIA N Y 6d 13 4 1
  1. PFS Progression-free survival, N no progression during follow-up, m months, CRT Chemoradiotherapy, NA Not Available